Todd Pitts
Concepts (396)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 24 | 2024 | 730 | 2.970 |
Why?
| Xenograft Model Antitumor Assays | 38 | 2024 | 797 | 2.060 |
Why?
| Protein Kinase Inhibitors | 19 | 2020 | 870 | 1.890 |
Why?
| Antineoplastic Agents | 25 | 2020 | 2038 | 1.480 |
Why?
| Triple Negative Breast Neoplasms | 7 | 2024 | 185 | 1.480 |
Why?
| Azepines | 5 | 2024 | 87 | 1.410 |
Why?
| Histone Deacetylase Inhibitors | 5 | 2024 | 206 | 1.260 |
Why?
| Cell Line, Tumor | 37 | 2025 | 3100 | 1.200 |
Why?
| Pyrimidines | 9 | 2020 | 444 | 1.200 |
Why?
| Mice, Nude | 25 | 2024 | 680 | 1.160 |
Why?
| Pyrazines | 6 | 2018 | 88 | 1.030 |
Why?
| Cell Proliferation | 22 | 2024 | 2337 | 0.970 |
Why?
| Pancreatic Neoplasms | 6 | 2024 | 878 | 0.920 |
Why?
| Carcinoma, Pancreatic Ductal | 2 | 2024 | 264 | 0.860 |
Why?
| Apoptosis | 22 | 2024 | 2481 | 0.790 |
Why?
| Fluorouracil | 1 | 2022 | 198 | 0.760 |
Why?
| Proto-Oncogene Proteins | 6 | 2018 | 636 | 0.640 |
Why?
| Camptothecin | 5 | 2022 | 106 | 0.640 |
Why?
| Benzimidazoles | 6 | 2024 | 158 | 0.640 |
Why?
| Imidazoles | 4 | 2018 | 224 | 0.640 |
Why?
| Aurora Kinase A | 4 | 2020 | 55 | 0.630 |
Why?
| Drug Resistance, Neoplasm | 12 | 2024 | 732 | 0.610 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1570 | 0.580 |
Why?
| Drug Synergism | 4 | 2014 | 354 | 0.560 |
Why?
| Mice | 42 | 2025 | 16543 | 0.560 |
Why?
| Neoplasms | 9 | 2022 | 2426 | 0.530 |
Why?
| Cell Cycle Proteins | 2 | 2018 | 576 | 0.510 |
Why?
| Wnt Signaling Pathway | 5 | 2024 | 164 | 0.500 |
Why?
| Cell Cycle Checkpoints | 3 | 2019 | 95 | 0.490 |
Why?
| Hydroxamic Acids | 3 | 2011 | 88 | 0.490 |
Why?
| Deoxycytidine | 3 | 2024 | 163 | 0.490 |
Why?
| Animals | 47 | 2025 | 34628 | 0.480 |
Why?
| Melanoma | 5 | 2024 | 735 | 0.470 |
Why?
| Receptor, IGF Type 1 | 3 | 2013 | 63 | 0.470 |
Why?
| Disease Models, Animal | 11 | 2025 | 3994 | 0.470 |
Why?
| Pyrazoles | 5 | 2018 | 403 | 0.460 |
Why?
| Gene Expression Regulation, Neoplastic | 10 | 2024 | 1312 | 0.450 |
Why?
| Tumor Microenvironment | 5 | 2022 | 588 | 0.450 |
Why?
| Antimitotic Agents | 1 | 2013 | 8 | 0.450 |
Why?
| Adrenocortical Carcinoma | 3 | 2020 | 64 | 0.450 |
Why?
| Mitogen-Activated Protein Kinases | 3 | 2014 | 311 | 0.440 |
Why?
| Tumor Suppressor Protein p53 | 5 | 2024 | 508 | 0.440 |
Why?
| Molecular Targeted Therapy | 3 | 2024 | 381 | 0.430 |
Why?
| Signal Transduction | 18 | 2024 | 4857 | 0.420 |
Why?
| G2 Phase Cell Cycle Checkpoints | 4 | 2022 | 45 | 0.420 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2018 | 379 | 0.410 |
Why?
| Cyclin-Dependent Kinases | 1 | 2013 | 129 | 0.410 |
Why?
| Boronic Acids | 2 | 2011 | 37 | 0.400 |
Why?
| Quinoxalines | 4 | 2020 | 64 | 0.380 |
Why?
| Dasatinib | 2 | 2024 | 50 | 0.370 |
Why?
| Gene Expression Profiling | 8 | 2024 | 1694 | 0.360 |
Why?
| Colonic Neoplasms | 2 | 2013 | 234 | 0.350 |
Why?
| Biomarkers, Tumor | 6 | 2018 | 1170 | 0.350 |
Why?
| Drug Screening Assays, Antitumor | 5 | 2020 | 195 | 0.340 |
Why?
| Humans | 67 | 2025 | 128896 | 0.340 |
Why?
| Heterografts | 3 | 2021 | 129 | 0.340 |
Why?
| Programmed Cell Death 1 Receptor | 3 | 2025 | 225 | 0.330 |
Why?
| Oxidoreductases Acting on CH-CH Group Donors | 2 | 2020 | 23 | 0.320 |
Why?
| Phosphatidylinositol 3-Kinases | 6 | 2018 | 359 | 0.310 |
Why?
| Adrenal Cortex Neoplasms | 2 | 2020 | 62 | 0.290 |
Why?
| Cell Cycle | 7 | 2018 | 581 | 0.290 |
Why?
| Ephrin-B2 | 2 | 2019 | 50 | 0.290 |
Why?
| Piperazines | 2 | 2020 | 326 | 0.290 |
Why?
| Enzyme Inhibitors | 5 | 2020 | 827 | 0.290 |
Why?
| Drug Delivery Systems | 1 | 2010 | 328 | 0.280 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 750 | 0.280 |
Why?
| Quinazolines | 3 | 2015 | 245 | 0.270 |
Why?
| Female | 41 | 2025 | 68162 | 0.260 |
Why?
| Anilides | 2 | 2018 | 72 | 0.260 |
Why?
| Oncogene Proteins, Fusion | 2 | 2018 | 195 | 0.260 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 3 | 2019 | 130 | 0.260 |
Why?
| Organoids | 2 | 2024 | 100 | 0.250 |
Why?
| Mutation | 9 | 2018 | 3671 | 0.250 |
Why?
| Cyclosporine | 2 | 2018 | 172 | 0.250 |
Why?
| Gene Dosage | 4 | 2015 | 143 | 0.250 |
Why?
| Nephritis, Interstitial | 1 | 2025 | 13 | 0.240 |
Why?
| Gene Regulatory Networks | 2 | 2024 | 278 | 0.240 |
Why?
| Immunoblotting | 6 | 2015 | 302 | 0.240 |
Why?
| Pyrimidinones | 2 | 2015 | 101 | 0.230 |
Why?
| Proto-Oncogene Proteins B-raf | 3 | 2018 | 210 | 0.230 |
Why?
| RNA, Small Interfering | 2 | 2024 | 575 | 0.220 |
Why?
| Lymphocytes, Tumor-Infiltrating | 3 | 2020 | 203 | 0.220 |
Why?
| Endogenous Retroviruses | 1 | 2024 | 30 | 0.220 |
Why?
| ras Proteins | 4 | 2013 | 150 | 0.220 |
Why?
| Proto-Oncogene Proteins p21(ras) | 6 | 2016 | 264 | 0.220 |
Why?
| Bevacizumab | 1 | 2024 | 130 | 0.220 |
Why?
| Mucous Membrane | 1 | 2024 | 122 | 0.220 |
Why?
| Pyridones | 2 | 2015 | 158 | 0.220 |
Why?
| Receptor, Notch1 | 2 | 2015 | 62 | 0.220 |
Why?
| Neoplasm Transplantation | 4 | 2018 | 254 | 0.210 |
Why?
| Paclitaxel | 1 | 2024 | 214 | 0.210 |
Why?
| Pyridines | 2 | 2018 | 472 | 0.210 |
Why?
| Antineoplastic Agents, Immunological | 3 | 2020 | 170 | 0.210 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 65 | 0.200 |
Why?
| HCT116 Cells | 3 | 2018 | 77 | 0.200 |
Why?
| Immunotherapy | 3 | 2022 | 579 | 0.200 |
Why?
| Doxorubicin | 1 | 2024 | 319 | 0.200 |
Why?
| Drug Design | 2 | 2013 | 156 | 0.190 |
Why?
| beta Catenin | 2 | 2020 | 220 | 0.190 |
Why?
| Gene Knockdown Techniques | 4 | 2020 | 315 | 0.180 |
Why?
| Momordica charantia | 1 | 2020 | 15 | 0.180 |
Why?
| DNA-Binding Proteins | 2 | 2020 | 1423 | 0.170 |
Why?
| Benzoxazoles | 1 | 2020 | 20 | 0.170 |
Why?
| HT29 Cells | 2 | 2018 | 36 | 0.170 |
Why?
| Neoplasms, Experimental | 2 | 2019 | 168 | 0.170 |
Why?
| Immune System | 1 | 2021 | 175 | 0.170 |
Why?
| eIF-2 Kinase | 1 | 2019 | 30 | 0.160 |
Why?
| src-Family Kinases | 2 | 2017 | 94 | 0.160 |
Why?
| Inhibitory Concentration 50 | 2 | 2016 | 83 | 0.160 |
Why?
| Receptor, EphB4 | 1 | 2019 | 36 | 0.160 |
Why?
| Tumor Burden | 2 | 2018 | 284 | 0.160 |
Why?
| DNA Helicases | 1 | 2020 | 149 | 0.150 |
Why?
| Plant Extracts | 1 | 2020 | 179 | 0.150 |
Why?
| Breast Neoplasms, Male | 1 | 2018 | 28 | 0.150 |
Why?
| Coenzymes | 1 | 2018 | 17 | 0.150 |
Why?
| 4-Aminobenzoic Acid | 1 | 2018 | 7 | 0.150 |
Why?
| MAP Kinase Kinase Kinases | 2 | 2015 | 70 | 0.150 |
Why?
| Thermodynamics | 1 | 2020 | 403 | 0.150 |
Why?
| Neoplasm Proteins | 2 | 2020 | 428 | 0.150 |
Why?
| Adrenal Cortex | 1 | 2018 | 27 | 0.150 |
Why?
| Septins | 1 | 2018 | 43 | 0.150 |
Why?
| Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.150 |
Why?
| Neoplasm Invasiveness | 3 | 2020 | 479 | 0.150 |
Why?
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 33 | 0.140 |
Why?
| Kidney | 1 | 2025 | 1330 | 0.140 |
Why?
| Angiogenesis Inhibitors | 3 | 2018 | 221 | 0.140 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 86 | 0.140 |
Why?
| Ubiquitin-Activating Enzymes | 1 | 2016 | 16 | 0.140 |
Why?
| Cyclopentanes | 1 | 2016 | 19 | 0.130 |
Why?
| Skin Neoplasms | 1 | 2024 | 828 | 0.130 |
Why?
| Transplantation, Heterologous | 4 | 2022 | 190 | 0.130 |
Why?
| Tumor Cells, Cultured | 4 | 2020 | 928 | 0.130 |
Why?
| Corynebacterium | 1 | 2017 | 48 | 0.130 |
Why?
| Corynebacterium Infections | 1 | 2017 | 40 | 0.130 |
Why?
| Tankyrases | 1 | 2016 | 13 | 0.130 |
Why?
| Cetuximab | 1 | 2016 | 93 | 0.130 |
Why?
| Insulin-Like Growth Factor I | 1 | 2018 | 308 | 0.130 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 114 | 0.130 |
Why?
| Capecitabine | 1 | 2015 | 48 | 0.130 |
Why?
| Autophagy | 1 | 2018 | 263 | 0.130 |
Why?
| Biliary Tract Neoplasms | 1 | 2015 | 25 | 0.130 |
Why?
| Amyloid Precursor Protein Secretases | 2 | 2013 | 78 | 0.130 |
Why?
| Drug Discovery | 1 | 2016 | 130 | 0.120 |
Why?
| Genes, ras | 2 | 2018 | 97 | 0.120 |
Why?
| Adenocarcinoma | 2 | 2020 | 895 | 0.120 |
Why?
| Cell Survival | 3 | 2019 | 1082 | 0.120 |
Why?
| Diphenylamine | 1 | 2014 | 8 | 0.120 |
Why?
| Gene Expression Regulation | 1 | 2024 | 2520 | 0.120 |
Why?
| Germ-Line Mutation | 2 | 2018 | 140 | 0.120 |
Why?
| Middle Aged | 14 | 2024 | 30977 | 0.110 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 172 | 0.110 |
Why?
| Piperidines | 1 | 2015 | 186 | 0.110 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2014 | 75 | 0.110 |
Why?
| Benzamides | 1 | 2014 | 191 | 0.110 |
Why?
| Protein Kinases | 1 | 2015 | 305 | 0.110 |
Why?
| Urinary Bladder Neoplasms | 1 | 2016 | 224 | 0.110 |
Why?
| Aged | 11 | 2024 | 22035 | 0.110 |
Why?
| Up-Regulation | 1 | 2016 | 848 | 0.110 |
Why?
| Receptor, Insulin | 1 | 2013 | 99 | 0.110 |
Why?
| Tetrahydronaphthalenes | 1 | 2013 | 30 | 0.110 |
Why?
| Valine | 1 | 2013 | 78 | 0.100 |
Why?
| Neutrophils | 4 | 2019 | 1203 | 0.100 |
Why?
| Receptors, Notch | 1 | 2013 | 85 | 0.100 |
Why?
| Bortezomib | 2 | 2011 | 44 | 0.100 |
Why?
| Mitosis | 1 | 2013 | 177 | 0.100 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 313 | 0.100 |
Why?
| Sirolimus | 1 | 2013 | 194 | 0.100 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 189 | 0.090 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 137 | 0.090 |
Why?
| Head and Neck Neoplasms | 1 | 2016 | 527 | 0.090 |
Why?
| Carcinoma, Squamous Cell | 1 | 2016 | 626 | 0.090 |
Why?
| Computational Biology | 1 | 2015 | 587 | 0.090 |
Why?
| Aldehyde Dehydrogenase | 1 | 2012 | 103 | 0.090 |
Why?
| Proteasome Inhibitors | 1 | 2011 | 44 | 0.090 |
Why?
| Benzodioxoles | 1 | 2012 | 102 | 0.090 |
Why?
| Carcinogenesis | 2 | 2024 | 200 | 0.090 |
Why?
| Proto-Oncogene Proteins c-akt | 4 | 2018 | 418 | 0.090 |
Why?
| Protease Inhibitors | 1 | 2011 | 104 | 0.090 |
Why?
| Nuclear Proteins | 1 | 2015 | 644 | 0.090 |
Why?
| Neoplasm Metastasis | 3 | 2018 | 608 | 0.090 |
Why?
| Mice, Inbred NOD | 2 | 2022 | 579 | 0.080 |
Why?
| Phosphorylation | 4 | 2019 | 1685 | 0.080 |
Why?
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 6 | 0.080 |
Why?
| Adult | 12 | 2024 | 35361 | 0.080 |
Why?
| Breast Neoplasms | 2 | 2012 | 2112 | 0.080 |
Why?
| Mice, Inbred BALB C | 3 | 2020 | 1230 | 0.080 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 70 | 0.080 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 81 | 0.080 |
Why?
| Male | 15 | 2024 | 63146 | 0.080 |
Why?
| Gastrointestinal Neoplasms | 1 | 2009 | 72 | 0.080 |
Why?
| Carcinoma, Hepatocellular | 1 | 2011 | 267 | 0.080 |
Why?
| Immunosuppressive Agents | 1 | 2013 | 699 | 0.080 |
Why?
| Cell Movement | 2 | 2011 | 932 | 0.080 |
Why?
| Positron-Emission Tomography | 3 | 2018 | 284 | 0.070 |
Why?
| Prognosis | 4 | 2019 | 3787 | 0.070 |
Why?
| Farnesyltranstransferase | 1 | 2007 | 35 | 0.070 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 772 | 0.070 |
Why?
| Protein Conformation | 2 | 2020 | 851 | 0.070 |
Why?
| Feasibility Studies | 1 | 2010 | 859 | 0.070 |
Why?
| Microsatellite Repeats | 2 | 2024 | 163 | 0.060 |
Why?
| Algorithms | 3 | 2024 | 1626 | 0.060 |
Why?
| Transcription, Genetic | 2 | 2024 | 1408 | 0.060 |
Why?
| Gene Expression | 2 | 2019 | 1476 | 0.060 |
Why?
| Maximum Tolerated Dose | 2 | 2020 | 195 | 0.060 |
Why?
| Reproducibility of Results | 2 | 2010 | 3042 | 0.060 |
Why?
| Quinolones | 1 | 2007 | 123 | 0.060 |
Why?
| Ipilimumab | 1 | 2025 | 29 | 0.060 |
Why?
| Neovascularization, Pathologic | 2 | 2018 | 293 | 0.060 |
Why?
| CTLA-4 Antigen | 1 | 2025 | 88 | 0.060 |
Why?
| Models, Molecular | 2 | 2020 | 1477 | 0.060 |
Why?
| Structure-Activity Relationship | 2 | 2018 | 539 | 0.050 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2019 | 35 | 0.050 |
Why?
| Enhancer Elements, Genetic | 1 | 2024 | 177 | 0.050 |
Why?
| Magnetic Resonance Spectroscopy | 2 | 2018 | 510 | 0.050 |
Why?
| Triazoles | 1 | 2024 | 153 | 0.050 |
Why?
| HMGB1 Protein | 1 | 2003 | 48 | 0.050 |
Why?
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 45 | 0.050 |
Why?
| Adrenergic alpha-Agonists | 1 | 2002 | 30 | 0.050 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2002 | 34 | 0.050 |
Why?
| Neuroimmunomodulation | 1 | 2002 | 67 | 0.050 |
Why?
| Histones | 2 | 2022 | 584 | 0.050 |
Why?
| Histone Deacetylase 1 | 1 | 2022 | 22 | 0.050 |
Why?
| Treatment Outcome | 4 | 2024 | 10239 | 0.050 |
Why?
| Isoenzymes | 1 | 2003 | 303 | 0.050 |
Why?
| Aurora Kinases | 2 | 2012 | 29 | 0.050 |
Why?
| Adrenergic beta-Agonists | 1 | 2002 | 132 | 0.050 |
Why?
| Endotoxemia | 1 | 2002 | 95 | 0.050 |
Why?
| Genetic Predisposition to Disease | 1 | 2010 | 2270 | 0.050 |
Why?
| Caspase 3 | 2 | 2013 | 241 | 0.050 |
Why?
| Acetylation | 1 | 2022 | 235 | 0.050 |
Why?
| Chimerism | 1 | 2021 | 29 | 0.050 |
Why?
| Flow Cytometry | 2 | 2019 | 1146 | 0.050 |
Why?
| Campylobacter jejuni | 1 | 2000 | 11 | 0.050 |
Why?
| Lymphoid Tissue | 1 | 2021 | 68 | 0.040 |
Why?
| Lymphocyte Subsets | 1 | 2021 | 85 | 0.040 |
Why?
| Cluster Analysis | 2 | 2012 | 479 | 0.040 |
Why?
| Catalase | 1 | 2000 | 122 | 0.040 |
Why?
| TCF Transcription Factors | 1 | 2020 | 16 | 0.040 |
Why?
| Adrenergic beta-Antagonists | 1 | 2002 | 320 | 0.040 |
Why?
| Mice, SCID | 1 | 2021 | 340 | 0.040 |
Why?
| Histone Deacetylases | 1 | 2022 | 211 | 0.040 |
Why?
| RNA, Neoplasm | 1 | 2020 | 89 | 0.040 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2020 | 90 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 59 | 0.040 |
Why?
| Indolizines | 1 | 2019 | 4 | 0.040 |
Why?
| Forkhead Box Protein M1 | 1 | 2019 | 6 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 114 | 0.040 |
Why?
| Small Molecule Libraries | 1 | 2020 | 85 | 0.040 |
Why?
| Genomics | 1 | 2024 | 715 | 0.040 |
Why?
| MAP Kinase Kinase 2 | 2 | 2013 | 28 | 0.040 |
Why?
| Crystallography, X-Ray | 1 | 2020 | 436 | 0.040 |
Why?
| MAP Kinase Kinase 1 | 2 | 2013 | 76 | 0.040 |
Why?
| High-Throughput Screening Assays | 1 | 2020 | 134 | 0.040 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| Genetic Linkage | 1 | 1999 | 298 | 0.040 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2020 | 190 | 0.040 |
Why?
| Flavin-Adenine Dinucleotide | 1 | 2018 | 14 | 0.040 |
Why?
| NADP | 1 | 2018 | 44 | 0.040 |
Why?
| Radiotherapy | 1 | 2019 | 186 | 0.040 |
Why?
| Hemorrhage | 1 | 2002 | 658 | 0.040 |
Why?
| Multifactorial Inheritance | 1 | 1999 | 148 | 0.040 |
Why?
| Nausea | 1 | 2018 | 104 | 0.040 |
Why?
| Aldosterone | 1 | 2018 | 43 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2020 | 861 | 0.040 |
Why?
| DNA Damage | 1 | 2020 | 377 | 0.040 |
Why?
| Area Under Curve | 1 | 2018 | 285 | 0.040 |
Why?
| Breast | 1 | 2018 | 149 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2020 | 1020 | 0.040 |
Why?
| RNA | 1 | 2024 | 877 | 0.040 |
Why?
| Diarrhea | 1 | 2018 | 179 | 0.040 |
Why?
| Catalytic Domain | 1 | 2018 | 217 | 0.030 |
Why?
| Autistic Disorder | 1 | 1999 | 184 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2020 | 1304 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2018 | 657 | 0.030 |
Why?
| RNA, Messenger | 2 | 2020 | 2700 | 0.030 |
Why?
| Ubiquitination | 1 | 2016 | 96 | 0.030 |
Why?
| Axin Protein | 1 | 2016 | 18 | 0.030 |
Why?
| Fatigue | 1 | 2018 | 319 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2018 | 422 | 0.030 |
Why?
| Protein Isoforms | 1 | 2017 | 369 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2019 | 377 | 0.030 |
Why?
| Hypertension | 2 | 2018 | 1236 | 0.030 |
Why?
| Administration, Oral | 1 | 2018 | 783 | 0.030 |
Why?
| Jagged-1 Protein | 1 | 2015 | 24 | 0.030 |
Why?
| Serrate-Jagged Proteins | 1 | 2015 | 29 | 0.030 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 576 | 0.030 |
Why?
| Tumor Protein p73 | 1 | 2015 | 14 | 0.030 |
Why?
| Gene Duplication | 1 | 2015 | 67 | 0.030 |
Why?
| Binding Sites | 1 | 2018 | 1238 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2019 | 1694 | 0.030 |
Why?
| Biopsy | 1 | 2018 | 1093 | 0.030 |
Why?
| NF-kappa B | 3 | 2003 | 685 | 0.030 |
Why?
| Databases, Genetic | 1 | 2015 | 226 | 0.030 |
Why?
| Mice, Knockout | 1 | 2021 | 2770 | 0.030 |
Why?
| Calcium-Binding Proteins | 1 | 2015 | 213 | 0.030 |
Why?
| Caspase 7 | 1 | 2013 | 22 | 0.030 |
Why?
| Butadienes | 1 | 2013 | 35 | 0.030 |
Why?
| Cell Growth Processes | 1 | 2013 | 52 | 0.030 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 376 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 1282 | 0.030 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 824 | 0.030 |
Why?
| Tumor Stem Cell Assay | 1 | 2012 | 32 | 0.030 |
Why?
| Nitriles | 1 | 2013 | 161 | 0.030 |
Why?
| Everolimus | 1 | 2013 | 69 | 0.030 |
Why?
| Random Allocation | 1 | 2013 | 351 | 0.030 |
Why?
| Phenotype | 1 | 2021 | 3059 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2015 | 1285 | 0.020 |
Why?
| Cyclic AMP Response Element-Binding Protein | 2 | 2003 | 138 | 0.020 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2003 | 267 | 0.020 |
Why?
| Immunoprecipitation | 1 | 2012 | 159 | 0.020 |
Why?
| Calcium Signaling | 1 | 2013 | 236 | 0.020 |
Why?
| Kinetics | 1 | 2014 | 1619 | 0.020 |
Why?
| PTEN Phosphohydrolase | 1 | 2012 | 148 | 0.020 |
Why?
| Cellular Senescence | 1 | 2012 | 176 | 0.020 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2012 | 319 | 0.020 |
Why?
| Enzyme Activation | 2 | 2003 | 811 | 0.020 |
Why?
| Disease Progression | 1 | 2018 | 2603 | 0.020 |
Why?
| Li-Fraumeni Syndrome | 1 | 2010 | 13 | 0.020 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2011 | 145 | 0.020 |
Why?
| Receptor, ErbB-2 | 1 | 2012 | 333 | 0.020 |
Why?
| Molecular Epidemiology | 1 | 2010 | 62 | 0.020 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 248 | 0.020 |
Why?
| Neutropenia | 1 | 2010 | 135 | 0.020 |
Why?
| Population Groups | 1 | 2010 | 60 | 0.020 |
Why?
| Metabolome | 1 | 2013 | 316 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2010 | 109 | 0.020 |
Why?
| Ligands | 1 | 2011 | 614 | 0.020 |
Why?
| Capillary Permeability | 1 | 2010 | 141 | 0.020 |
Why?
| Transcriptome | 1 | 2015 | 871 | 0.020 |
Why?
| Drug Combinations | 1 | 2010 | 327 | 0.020 |
Why?
| Australia | 1 | 2010 | 247 | 0.020 |
Why?
| Keratinocytes | 1 | 2010 | 240 | 0.020 |
Why?
| Membrane Proteins | 1 | 2015 | 1100 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 2015 | 1359 | 0.020 |
Why?
| Biomarkers | 1 | 2019 | 3874 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 957 | 0.020 |
Why?
| Sulfonamides | 1 | 2011 | 494 | 0.020 |
Why?
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2007 | 13 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 822 | 0.020 |
Why?
| Verapamil | 1 | 2007 | 38 | 0.020 |
Why?
| Calcium | 1 | 2013 | 1173 | 0.020 |
Why?
| Blotting, Western | 1 | 2009 | 1188 | 0.020 |
Why?
| Clone Cells | 1 | 2007 | 257 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2018 | 3348 | 0.020 |
Why?
| Calcium Channel Blockers | 1 | 2007 | 125 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2010 | 1968 | 0.020 |
Why?
| Metabolomics | 1 | 2011 | 592 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2011 | 637 | 0.020 |
Why?
| Family | 1 | 2010 | 650 | 0.020 |
Why?
| MicroRNAs | 1 | 2012 | 668 | 0.020 |
Why?
| Cohort Studies | 1 | 2015 | 5394 | 0.020 |
Why?
| Ovarian Neoplasms | 1 | 2010 | 474 | 0.010 |
Why?
| Phosphotransferases | 1 | 2003 | 26 | 0.010 |
Why?
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2003 | 4 | 0.010 |
Why?
| bcl-Associated Death Protein | 1 | 2003 | 7 | 0.010 |
Why?
| Phentolamine | 1 | 2002 | 14 | 0.010 |
Why?
| Ribosomal Protein S6 Kinases | 1 | 2002 | 21 | 0.010 |
Why?
| Brimonidine Tartrate | 1 | 2002 | 9 | 0.010 |
Why?
| Adolescent | 2 | 2018 | 20197 | 0.010 |
Why?
| Phenylephrine | 1 | 2002 | 75 | 0.010 |
Why?
| Propranolol | 1 | 2002 | 49 | 0.010 |
Why?
| Mice, Mutant Strains | 1 | 2003 | 291 | 0.010 |
Why?
| Peroxidase | 1 | 2002 | 183 | 0.010 |
Why?
| Chemokines | 1 | 2003 | 227 | 0.010 |
Why?
| Young Adult | 1 | 2018 | 12286 | 0.010 |
Why?
| Biological Transport | 1 | 2003 | 394 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 154 | 0.010 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 228 | 0.010 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 134 | 0.010 |
Why?
| Respiratory Burst | 1 | 2000 | 16 | 0.010 |
Why?
| omega-N-Methylarginine | 1 | 2000 | 26 | 0.010 |
Why?
| MAP Kinase Signaling System | 1 | 2002 | 305 | 0.010 |
Why?
| Inflammation Mediators | 1 | 2003 | 503 | 0.010 |
Why?
| Protein Processing, Post-Translational | 1 | 2002 | 448 | 0.010 |
Why?
| Statistical Distributions | 1 | 1999 | 7 | 0.010 |
Why?
| Matched-Pair Analysis | 1 | 1999 | 44 | 0.010 |
Why?
| Cloning, Molecular | 1 | 2000 | 536 | 0.010 |
Why?
| Intelligence Tests | 1 | 1999 | 59 | 0.010 |
Why?
| Chromosomes, Human | 1 | 1999 | 41 | 0.010 |
Why?
| Nuclear Family | 1 | 1999 | 50 | 0.010 |
Why?
| Lipopolysaccharides | 1 | 2003 | 877 | 0.010 |
Why?
| Protein-Tyrosine Kinases | 1 | 2002 | 421 | 0.010 |
Why?
| Hydrogen Peroxide | 1 | 2000 | 310 | 0.010 |
Why?
| Linkage Disequilibrium | 1 | 1999 | 255 | 0.010 |
Why?
| Carrier Proteins | 1 | 2003 | 728 | 0.010 |
Why?
| Models, Genetic | 1 | 1999 | 586 | 0.010 |
Why?
| Cells, Cultured | 1 | 2003 | 4048 | 0.010 |
Why?
| Cytokines | 1 | 2003 | 1995 | 0.010 |
Why?
| Cell Line | 1 | 2000 | 2759 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 1999 | 2842 | 0.010 |
Why?
| Genotype | 1 | 1999 | 1834 | 0.010 |
Why?
| Sex Factors | 1 | 1999 | 1947 | 0.010 |
Why?
| Macrophages | 1 | 2000 | 1452 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 2003 | 5270 | 0.010 |
Why?
| Child, Preschool | 1 | 1999 | 10457 | 0.000 |
Why?
| Child | 1 | 1999 | 20824 | 0.000 |
Why?
|
|
Pitts's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|